A detailed history of Summit Trail Advisors, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Summit Trail Advisors, LLC holds 7,608 shares of LLY stock, worth $6.89 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
7,608
Previous 6,964 9.25%
Holding current value
$6.89 Million
Previous $4.06 Million 45.8%
% of portfolio
0.16%
Previous 0.14%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$592.2 - $792.28 $381,376 - $510,228
644 Added 9.25%
7,608 $5.92 Million
Q4 2023

Feb 06, 2024

SELL
$525.19 - $619.13 $45,691 - $53,864
-87 Reduced 1.23%
6,964 $4.06 Million
Q3 2023

Oct 30, 2023

BUY
$434.7 - $599.3 $180,835 - $249,308
416 Added 6.27%
7,051 $3.79 Million
Q2 2023

Jul 25, 2023

BUY
$350.74 - $468.98 $1.24 Million - $1.66 Million
3,531 Added 113.76%
6,635 $3.11 Million
Q1 2023

May 04, 2023

BUY
$310.63 - $364.82 $196,939 - $231,295
634 Added 25.67%
3,104 $1.07 Million
Q4 2022

Feb 07, 2023

BUY
$321.55 - $374.67 $63,023 - $73,435
196 Added 8.62%
2,470 $903,000
Q3 2022

Nov 09, 2022

BUY
$296.48 - $337.87 $193,601 - $220,629
653 Added 40.28%
2,274 $735,000
Q2 2022

Aug 09, 2022

BUY
$278.73 - $327.27 $174,763 - $205,198
627 Added 63.08%
1,621 $526,000
Q1 2022

May 16, 2022

BUY
$234.69 - $291.66 $234 - $291
1 Added 0.1%
994 $285,000
Q4 2021

Feb 11, 2022

BUY
$224.85 - $279.04 $223,276 - $277,086
993 New
993 $274,000
Q2 2018

Aug 10, 2018

SELL
$75.7 - $86.88 $224,601 - $257,772
-2,967 Closed
0 $0
Q1 2018

May 22, 2018

SELL
$74.21 - $87.6 $17.4 Million - $20.5 Million
-234,266 Reduced 98.75%
2,967 $237,000
Q1 2018

May 21, 2018

BUY
$74.21 - $87.6 $17.4 Million - $20.5 Million
233,930 Added 7082.35%
237,233 $237,000
Q4 2017

Feb 14, 2018

BUY
$81.94 - $87.89 $270,647 - $290,300
3,303
3,303 $279,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $860B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Summit Trail Advisors, LLC Portfolio

Follow Summit Trail Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Trail Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Trail Advisors, LLC with notifications on news.